Benchmarking Outcomes for Molecularly Characterized Synchronous Oligo metastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival

Authors

Brian De
Ahsan S Farooqi
Kyle G Mitchell
Ethan B Ludmir
Jeff Lewis
Waree Rinsurongkawong
Vadeerat Rinsurongkawong
J Jack Lee
Stephen G Swisher
Don L Gibbons
Jianjun Zhang
Xiuning Le
Yasir Y Elamin
Daniel R Gomez
Matthew S Ning
Steven H Lin
Zhongxing Liao
Joe Y Chang
Ara A Vaporciyan
John V Heymach
Mara B Antonoff
Saumil J Gandhi

Publication Date

1-7-2023

Journal

JCO Precision Oncology

Abstract

PURPOSE: Local consolidative therapy (LCT) for patients with synchronous oligometastatic non-small-cell lung cancer is an evolving treatment strategy, but outcomes following LCT stratified by genetic mutations have not been reported. We sought to identify genomic associations with overall survival (OS) and progression-free survival (PFS) for these patients.

METHODS: We identified all patients presenting between 2000 and 2017 with stage IV non-small-cell lung cancer and ≤ 3 synchronous metastatic sites. Patients were grouped according to mutational statuses. Primary outcomes included OS and PFS following initial diagnosis.

RESULTS: Of 194 included patients, 121 received comprehensive LCT to all sites of disease with either surgery or radiation.

CONCLUSION: When compared with wild-type patients, those with

Keywords

Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Benchmarking, Proto-Oncogene Proteins p21(ras), Mutation, ErbB Receptors

Comments

Data Availability Statement

PMID: 36716413